Our Team

Working For You

John Still

President and CEO

John is the founder and President of PharmaMetrics, Inc. With over 24 years of experience in Business Analysis and Pricing Methodology within the Managed Care and Managed Markets of the pharmaceutical industry, John has a deep understanding of both the financial and operational ends of the business.

Prior to launching PharmaMetrics, John spent more than twelve years at Rhone-Poulenc Rorer (currently Sanofi) and was responsible for all aspects of managed care and managed markets contract analysis across business channels. John became motivated to launch PharmaMetrics when he saw the Pharmaceutical industry struggle to analyze and comprehend the complexities of managed care contracting.

John has had articles published in Pharmaceutical Commerce Magazine and Pharmaceutical Executive Magazine.

He holds an MBA in Finance from Drexel University and a B.A. in Economics from Westminster College.

  •  “What sets PharmaMetrics apart is the depth and breadth of their true business knowledge.”
            -- Director, Contracts, Top 20 Pharma

  • “PharmaMetrics solutions can either be a complete business solution or independent modules that supplement your current business infrastructure.”
            -- Director, Contracts, Top 20 Pharma

  • “The implementation was easy and I didn’t need any training whatsoever. If you know how to do your job – the system follows your process. You don’t have to change your process to meet the systems needs.”
                -- Director, Corporate Compliance, Dermatological Company

  • “The industry experience and knowledge of their expanded team of experts sets them far apart from other service providers within the industry.”
                -- Director of Contracting, Amarin Pharma Inc.

  • “PharmaMetrics offers the services and software to handle all of our Managed Markets needs from front-end pricing analytics to the ban-end contract administration.”
            -- Sr. Director, Contract Management, Top 10 Pharma

  • “The robust reports generated enable more accurate forecasting and financial analysis.”
            -- Sr. Director, Top 10 Pharma